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Background: The revised 2008 World Health Organization classification maintains a histological grading system
(grades 1–3) for follicular lymphoma (FL). The value of grading FL has been debated. This study will yield deeper
insights into the morphologic, immunophenotypic characterization and t(14;18) translocation in FL and explore
their significance of diagnosis of Chinese FL subgroups.
Methods: We retrospectively reviewed the FL diagnoses according to the 2008 WHO classification in all diagnostic
specimens from a multicentric cohort of 122 Chinese patients. Upon review, 115 cases proved to be truly FL. CD10,
BCL6, MUM1, BCL2 and t(14;18) (q32;q21) translocation were detected by Envision immunostaining technique and
fluorescence in situ hybridization.
Results: FL1 has larger proportion of follicular pattern (93.0%) than that of FL2 (73.7%, P = 0.036), FL3B (63.6%,
P = 0.003) and FL3A (77.4%, P = 0.053), although the last P value was more than 0.05 (Pearson’s chi-squared test). Areas
of DLBCL were present in 25.8% (8/31) of FL3A and more frequent in FL3B (59.1%, 13/22; P = 0.015). The positivity of
CD10 and BCL2 in FL1-2 were significantly higher than those in FL3 (P < 0.001, P = 0.043, respectively). The positivity of
MUM1 in FL1-2 was significantly lower than that in FL3 (10.2% vs. 51.0%; P < 0.001). Furthermore the positivity of
MUM1 in FL3A was significantly lower than that in FL3B (37.9% vs. 68.2%; P = 0.032). The positivity of t(14;18) was
higher in FL1-2 than in FL3 (73.5% vs. 35.6%, P < 0.001), and was higher in FL3A than in FL3B (51.9% vs. 11.1%,
P = 0.005). t(14;18) was significantly correlated with CD10+ (R = 0.453, P < 0.001) and MUM1+ (R = −0.482, P < 0.001).
Conclusions: FL1 and FL2 were immunophenotypically and genomically similar, while FL3A and FL3B were partly
immunophenotypically similar but morphologically, genomically distinct. FL3A was genomically closer to FL1-2,
whereas FL3A was genomically closer DLBCL. Thus we hypothesize that FL may in fact be a heterogeneous indolent
lymphoma encompassing entities with distinct molecular pathogenesis and genetic characteristics.
Immunohistochemical and genetic characterization helps to distinguish subgroups of FLs.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1334018129864616.
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Follicular lymphoma (FL) is an indolent lymphoma. It ac-
counts for 22% of non-Hodgkin’s lymphoma and it is by
far the most frequent indolent lymphoma [1]. It is mainly
composed of centrocytes with a variable component of
centroblasts, the frequency of which gives the grade (1, 2
or 3, depending on the percentage of centroblasts).
Cluster of differentiation 10 (CD10) and B-Cell Lymph-
oma 6 (BCL6) are biomarker for centrocytes. Tumor cells
in typical FL positively express the two or one of the bio-
markers. Some cases, especially grade 3B (FL3B), may lack
CD10, but retain BCL6 expression [2-4]. Multiple myeloma
oncogene 1 (MUM1) is a marker for late germinal center B
cells (GCBs) and early post-GCBs [5]. According to our
clinical work and reports [3],a few FL are MUM1+. How-
ever the significance of expression of MUM1 in FL is still
unknown. Most FLs express the anti-apoptotic protein B
cell lymphoma 2 (BCL2), while follicles in reactive hyper-
plasia do not express BCL2. BCL2 positive is an important
factor for diagnosis and differential diagnosis of FL.
The t(14;18)(q32;q21) chromosome abnormality is the
genetic hallmark of FL. This abnormality juxtaposes the
VDJ region of the immunoglobulin heavy chain (IgH) gene
on chromosome 14q32 with BCL2 gene on chromosome
18q21, placing BCL2 under the regulatory control of the
IgH promotor and causing an overexpression of the BCL2
protein [6]. It is reported [3,7,8] that t(14;18) translocation
has been detected in only around 13% of FL3B compared
to 58-73% in FL3A and more than 85% of FL1-2. There is
no correlation between t(14:18) translocation and BCL2
expression [7].
Several studies have demonstrated that FL exhibits vari-
ous morphologies, phenotypes, genetic aberrations, and
clinical behaviors. These features vary greatly across geo-
graphic regions, suggesting geographic heterogeneity as a
characteristic of this type of lymphoma. By far, most re-
searches are based on Western population and only a few
studies compared the frequency of grade 3A (FL3A) and
3B FL3B cases. Therefore, this study was undertaken to re-
veal the morphological, immunophenotypic and genetic
features of FLs in China. We also investigated the relation-
ship between t(14:18) translocation and the histological
grade, as well as the biomarker expression profile of
CD10, BCL6, MUM1 and BCL2.
Methods
Patients
Biopsy material from 122 unselected cases of FL was re-
trieved from the surgical pathology and consultation files
at Guangdong General Hospital (Guangzhou, China), Sun
Yat-sen University Cancer Center (Guangzhou, China),
and the First Affiliated Hospital of Sun Yat-sen University
(Guangzhou, China) between 2001 and 2010. Archival
diagnostic paraffin blocks were available for all cases. Thetissue was fixed in 10% neutral buffered formalin, embed-
ded in paraffin, and processed routinely. Four-micrometer
sections were stained with H&E for routine histologic
evaluation. The histopathology of all cases was reviewed
by two of qualified pathologists (Yan-Hui Liu and Heng-
Guo Zhuang). Cases were evaluated and graded according
to 2008 World Health Organization (WHO) criteria. Upon
review, 115 cases proved to be truly FL, and 7 cases were
excluded (1 reactive disease, 3 diffuse large B-cell lymph-
omas, and 3 other types of low-grade B-cell lymphoma).
The ethics committee of Guangdong General Hospital &
Guangdong Academy of Medical Science approved the
study [Reference number No.GDREC2010147H].
Immunohistochemistry (IHC)
Immunohistochemistry staining was performed using Real
Envision Kit (K5007, DAKO, Carpinteria, CA) on an auto-
mated immunostaining module (DAKO) according to the
manufacturer’s instructions. The antibodies and dilutions
employed were as follows: CD10, clone 56C6, 1:100 dilu-
tion (Novocastra, Newcastle, UK); BCL2, clone 124, 1:50
dilution (DAKO); BCL6, clone PG-B6p, 1:100 dilution
(DAKO); and MUM1, clone MUM1p, 1:400 dilution
(DAKO). A negative control was performed in all cases by
omitting the primary antibody, which in all instances
resulted in negative immunoreactivity. In all cases, internal
control was used as positive control.
Only tumor tissues with distinct nuclear staining for
BCL6 and MUM1 in >30% of the tumor cells were recorded
as positive. Distinct membrane staining for CD10 in > 30%
of tumor cells and cytoplasm staining for BCL2 in > 30% of
tumor cells was recorded.
Fluorescence In Situ Hybridization (FISH)
FISH for t(14;18) (q32;q21) was performed on formalin-
fixed, paraffin-embedded tissue sections as previously de-
scribed [9] using a dual-fusion LSI IGH/BCL2 probe
(08L60-020, Vysis, Downers Grove, IL). FISH signals were
analyzed using a fluorescence microscope (Olympus
BX51, Tokyo, Japan) equipped with a DP72 camera and
DP2-BSW software (Olympus, Tokyo, Japan).
Tissue sections from twenty reactive lymph node speci-
mens were used to determine the cut-off level for IGH/
BCL2 probe. At least 100 intact nuclei per case were evalu-
ated. The mean plus three times the standard deviation
(mean + 3SDs) of the normal range was set as the reference
range [8]. The signal distribution was evaluated by two in-
dependent observers (Fen Zhang and Li-Xu Yan). Trans-
location of BCL2 was considered positive if they exceeded a
cutoff level of more than 5% of the tumor cells (Figure 1).
Statistical analysis
Statistical analysis was prepared using the Statistical Pack-
age of Social Sciences version 18.0 for Windows (SPSS,
Figure 1 FISH analysis of t(14;18) (q32;q21) translocation in representative patients with FL (original magnification ×40). (A) A patients
with low-grade FL. (B) A patients with high-grade FL. The dual-fusion and dual color IGH/BCL2 probe was used. The expected pattern in a
normal nucleus is the two orange, two green signal pattern (2O2G). Fusion signals (yellow arrows) represent fusion genes. In a nucleus harboring
a t(14;18), the most common pattern is 1O1G2F.
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histologic grade group, we performed Pearson’s chi-squared
test using a R × 2 contingency table. Because the propor-
tions of follicular and diffuse pattern, and focally follicular
pattern in each group were small, we analyzed the two
groups together as one group. We performed Pearson’s
Chi-square test and Fisher’s exact test to compare the inci-
dence of marker expressions and positive t(14;18) in each
histologic grade group. Spearman’s rank correlation was
used in correlation analysis. Results were considered statis-
tically significant when two-sided P < 0.05.Results
Clinical features
The median age of 115 patients with FL at diagnosis was 55
years (range, 22–86 years). Males were more affected than
females, with a male-to-female ratio of 1.4:1 (67:48). FL pre-
dominantly involved lymph nodes (100/115, 87.0%), but also
spleen (3/115, 2.6%) and Waldeyer ring (5/115, 4.3%). The
gastrointestinal tract cases involved 3 (2.6%) stomach and 1
(0.9%) ileocecal junction. Occasionally, FL involved parotid
(2/115, 1.7%), and thyroid gland (1/115, 0.9%).Morphology
Of 115 FLs, 43 (37.4%) were grade 1, 19 (16.5%) were
grade 2, and 53 (46.1%) were grade 3. FL1 has larger pro-
portion of follicular pattern (93.0%) than that of FL2
(73.7%, P = 0.050 0.036), FL3B (63.6%, P = 0.003) and
FL3A (77.4%, P = 0.053), although the last P value was
more than 0.05 (Pearson’s chi-squared test). The patterns
and grading of 115 FL cases are listed in Table 1. In our
study no DLBCL area was found in FL1-2. Areas of
DLBCL were present in 25.8% (8/31) of FL3A and more
frequent in FL3B (59.1%, 13/22; P = 0.015; (Table 2).Immunohistochemical analysis
Of 115 FLs, CD10 and BCL6 were successfully detected in
114 cases. BCL2 was successfully detected in 111 cases,
and MUM1 was detected in 110 cases. CD10 and BCL6
was positive not only at in the tumor follicles, but also at
in the interfollicular and diffuse areas of some cases
(Figure 2). The staining intensity of CD10 was relatively
uniform and the BCL6 staining intensity varies. Both
markers expressed stronger in the follicles than in
interfollicular and diffuse areas. The positive rate of CD10
in low grade (FL1-2) was significantly higher than that in
high grade (FL3; 95.1% vs. 66.0%, P < 0.001; Figure 2), and
it was also higher than that in FL3A (95.1% vs. 67.7%, P =
0.001 Table 3). There were no statistically significant dif-
ferences in BCL6 expressions between low grade and high
grade, FL1 and FL2, together with FL3A and FL3B
(Table 3).
The positive rate of MUM1 in low grade was signifi-
cantly lower than that in high grade (10.2% vs. 51.0%, P <
0.001; Figure 2, Table 3). Similar difference was found be-
tween FL1-2 and FL3A (10.2% vs. 37.9%, P = 0.002), FL3A
and FL3B (37.9% vs. 68.2%, P = 0.032). However, there was
no statistical difference in MUM1 expression between FL1
and FL2 (Table 3).
BCL2 protein was expressed with consistent high inten-
sity in the tumor cells in FL1 and FL2, but with inconsist-
ent median to week intensity in FL3, and negatively in
some large transformed cells in FL3 (Figure 2). Positive
rate of BCL2 in low grade was higher than that in high
grade (96.6% vs. 84.6%, P = 0.043; Table 4). But no differ-
ences were found between other groups.
Interestingly, data analyses revealed a negative correlation
between CD10 and MUM1 protein expression in total
cases (n = 110, R = −0.269, P = 0.005, Spearman’s rank cor-
relation; Table 5). The proportion of CD10-/MUM1+ in
low grade (1/59, 1.7%) was significantly lower than that in
Table 1 The patterns and grading of 115 FLs
Patterns Proportion follicular Grading
FL1 (N = 43) FL2 (N = 19) FL3A (N = 31) FL3B (N = 22)
n (%) n (%) n (%) n (%)
Follicular >75% 40 (93.0) 14 (73.7) 24 (77.4) 14 (63.6)
Follicular and diffuse 25-75% 1 (2.3) 2 (10.5) 2 (6.5) 4 (18.2)
Focally follicular/predominantly diffuse <25% 2 (4.7) 3 (15.8) 5 (16.1) 4 (18.2)
FL, follicular lymphomas; FL1, FL grade 1; FL2, FL grade 2; FL3A, FL grade 3A; FL3B, FL grade 3B.
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CD10-/MUM1+ tended to be lower in FL3A (4/29, 13.8%)
compared with that in FL3B (6/22, 27.3%); however, the dif-
ference was not statistically significant (P = 0.295, Pearson’s
chi-squared test).
Relationship among histological grades,
immunophenotyping and t(14;18) translocation by FISH
analysis
t(14;18)(q32;q21) (IGH/BCL2) translocation analysis by
FISH was successfully done in 94 of 115 FL cases. Repre-
sentative positive FISH image are shown in Figure 1.
The total positive rate of t(14;18) translocation was
55.3% (52/94). The t(14;18) translocation rate in low
grade was much higher than that in high grade (73.5%
vs. 35.6%, P < 0.001). The t(14;18) translocation rate in
FL3A was much higher than that in FL3B (51.9% vs.
11.1%, P = 0.005; Table 4).
The study showed that 60% (54/90) of FL expressed con-
sistent t(14;18) translocation and BCL2 expression, of
which 54.4% (49/90) was t(14;18)+/BCL2+ and 5.6% (5/90)
was t(14;18)-/BCL2-. The consistent rate of t(14;18) trans-
location and BCL2 expression decreased with the increase
of grading (Table 6). However, no correlations between t
(14;18) translocation and BCL2 or BCL6 expression
were found (Table 7). t(14;18) translocation was posi-
tively correlated to CD10+ (R = 0.453, P < 0.001), and
negatively correlated to MUM1+ (R = −0.482, P < 0.001;
Table 7). The t(14;18) translocation rates in CD10-/MUM-,
CD10-/MUM1+, CD10+/MUM1- and CD10+/MUM1+
subtypes were 12.5% (1/8), 10% (1/10), 25% (4/16) and
80.4% (45/56), respectively.Table 2 The patterns of high-grade FLs
Patterns High grade P*
FL3A (N = 31) FL3B (N = 22)
n (%) n (%)
Pure FL3 23 (74.2) 9 (40.9) 0.015
DLBCL with FL3# 8 (25.8) 13 (59.1)
*Pearson’s chi-squared test. #According to 2008 World Health Organization
(WHO) criteria, diffuse areas containing >15 centroblasts per high-power field
are reported as DLBCL with FL. Pure FL3, FL3 with 100% follicular pattern.
DLBCL, diffuse large B-cell lymphoma; FL3, FL grade 3; FL3A, FL grade 3A;
FL3B, FL grade 3B; High grade, grade 3.Discussions
FL is the most common of the indolent non-Hodgkin’s
lymphomas, and the second-most-common form of non-
Hodgkin’s lymphomas overall. Chinese FL had its unique
epidemiological and clinicalopathological features. This
study demonstrated a high proportion of FL3 (46.1%),
which was very close to a previous report (45.7%) on
Chinese cohort [10], but higher than that in western coun-
tries [11]. According to a nationwide multicenter study of
10002 cases [12], FL accounts for about 5.5% of all lymph-
omas in China. The incidence was close to those in Asia
and in developing countries, but much lower than those
in USA and Western Europe [13,14]. In published studies
[15,16], areas of DLBCL are present in 60-80% of FL3B
cases and less frequently in FL3A. Our results are very
close to those data.
FL is a neoplasm composed of germinal center (GC)
B-cells (typically both ceotrocytes and centroblasts cells).
FL cells typically express B-cell markers (CD19, CD20,
CD22, and CD79a), together with GC-markers (CD10
and BCL6) and BCL2 [11,17]. Some cases, especially
FL3B, may lack CD10, but retain BCL6 expression [2-4].
In our FL study CD10 positive rate significantly reduced
in high-grade FL compared with low-grade FL, Whereas
BCL6 seems to be a more reliable GC-marker than
CD10, as it is conserved in higher grade [11].
MUM1 is a marker for late germinal center B cells
(GCBs) and early post-GCBs [5]. In our FL series GC-
marker CD10 decreased with the increase of FL grade,
while post-GC marker MUM1 increased with the increase
of FL grade. There were eleven CD10-/MUM1+ cases, of
which ten were high grade and one was low grade. The only
one low-grade case was morphologically composed of large
central cells, and was t(14;18) translocation negative. This
was consisted with the previous report that FL composed
of large central cells is more aggressive than other low-
grade FL, and had lower CD10-positive rate and t(14;18)
translocation rate [8]. The proportion of CD10-/MUM1+
cases in CD10- FL rose from 55.0% to 80.0% if the cut-off
value for MUM1 positive decreased from 30% to 10%.
Hans’ algorithm [18] has been widely used as standard
to sub-classify DLBCL into (GCB) and non-GCB origins
[19]. If classified according to Hans’s algorithm, 80%
(16/20) of CD10- FL were NONnon-GCB subtype and
Figure 2 Immunohistochemical staining of specimens from representative patients with FL (original magnification ×400). (A) Strong
cytoplasmic expression of CD10 in a patient with low-grade FL. (E) Tumor cells are negative for CD10 in a patient with high grade FL. (B, C)
Weak to negative nuclear expression of BCL6 and MUM1 in a patient with low-grade FL. (F, G) Partial positivity of tumor cells for BCL6 and
MUM1 in a patient with high-grade FL. (D) BCL2 protein is expressed with consistent high intensity in the neoplastic cells in low-grade FL. (H)
BCL2 protein is expressed with inconsistent median to week intensity in high-grade FL, and expressed negatively in some large transformed cells.
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possible different origins of CD10-/MUM1+ and CD10-
/MUM1- FLs.
BCL2 is a well-known anti-apoptotic protein. Bcl-2
expressed in 91.0% of our FL cases, which falls at the higher
end of the reported range of 75-98% [20-22]. Besides, BCL2
protein is expressed by a variable proportion of the tumor
cells in 85-90% of cases of low-grade FL, but only 50% of
high-grade FL using standard antibodies [22]. Therefore, in
clinical work it must be recognized that absence of BCL2
protein dose not exclude FL. In this study, we found that
BCL2 was consistently strong in the tumor cells in low-
grade FLs, but was inconsistently medium to negative inTable 3 CD10, BCL6 and MUM1 protein expression the FL sub
FL grading CD10 positive
n/N (%) P n/N
FL1 40/42 (95.2) 1.000# 33/42
FL2 18/19 (94.7) 18/19
FL3A 21/31 (67.7) 0.756* 25/31
FL3B 14/22 (63.6) 17/22
FL1-2 58/61 (95.1) < 0.001* 51/61
FL3 35/53 (66.0) 42/53
FL1-2 58/61 (95.1) 0.001# 51/61
FL3A 21/31 (67.7) 25/31
FL1-3A 79/92 (85.9) 0.028# 76/92
FL3B 14/22 (63.6) 17/22
Total 93/114 (81.6) 93/11
*Pearson’s Chi-square test. #Fisher’s exact test. Bold text indicates significant P value
lymphomas; FL1, FL grade 1; FL2, FL grade 2; FL3A, FL grade 3A; FL3B, FL grade 3B.grade 3 FLs. Whether this is conducive to the diagnosis of
high-grade FL needs to be verified by more cases.
The t(14;18) translocation rate in FL1-2 in this study was
73.5%, which was close to Japanese data [23,24], and slightly
lower than most of the western reports (80-90%) [25]. This
difference may be caused by regional and ethnical differ-
ences. The t(14;18) translocation rate in FL3A (51.9%) was
close to that in low-grade FL (73.5%). While the rate in
FL3B (11.1%) was close to those reported in DLBCL [3]
and our previous study [26]. It was reported [24] that FLs
without t(14;18) are usually histological FL3B. This may
suggest that FLs without the t(14;18) are pathophysiologic-
ally distinct from those cases with BCL2 translocation.groups
BCL6 positive MUM1 positive
(%) P n/N (%) P
(78.6) 0.151# 3/40 (7.5) 0.376#
(94.7) 3/19 (15.8)
(80.6) 1.000# 11/29 (37.9) 0.032*
(77.3) 15/22 (68.2)
(83.6) 0.549* 6/59 (10.2) < 0.001*
(79.2) 26/51 (51.0)
(83.6) 0.723* 6/59 (10.2) 0.002*
(80.6) 11/29 (37.9)
(82.6) 0.550# 17/88 (19.3) < 0.001*
(77.3) 15/22 (68.2)
4 (81.6) 32/110 (29.1)
. n/N (%), number positive/total number tested (percentage). FL, follicular
Table 4 BCL2 protein expression and t(14;18)
translocation in the FL subgroups
FL grading BCL2 positive t(14;18) translocation
positive
n/N (%) P (R) n/N (%) P (R)
FL1 38/40 (95.0) 1.000# 22/32 (68.8) 0.498#
FL2 19/19 (100) 14/17 (82.4)
FL3A 25/30 (83.3) 1.000# 14/27 (51.9) 0.005*
FL3B 19/22 (86.4) 2/18 (11.1)
FL1-2 57/59 (96.6) 0.043# 36/49 (73.5) < 0.001*
FL3 44/52 (84.6) 16/45 (35.6)
FL1-2 57/59 (96.6) 0.114* 36/49 (73.5) 0.057*
FL3A 25/30 (83.3) 14/27 (51.9)
FL1-3A 82/89 (92.1) 0.412# 50/76 (65.8) < 0.001*
FL3B 19/22 (86.4) 2/18 (11.1)
Total 101/111 (91.0) 52/94 (55.3)
*Pearson’s Chi-square test. #Fisher’s exact test. Bold text indicates significant P
value. n/N (%), number positive/total number tested (percentage). FL, follicular
lymphomas; FL1, FL grade 1; FL2, FL grade 2; FL3A, FL grade 3A; FL3B, FL
grade 3B.
Table 6 The correlation between FL grading and t(14;18)
translocation and BCL2
FL FL1-2 (%) FL3A (%) FL3B (%) Total (%)
t(14;18)+/BCL2+ 34/46 (73.9) 13/26 (50.0) 2/18 (11.1) 49/90 (54.4)
t(14;18)-/BCL2- 1/46 (2.2) 3/26 (11.5) 1/18 (5.6) 5/90 (5.6)
t(14;18)+/BCL2- 1/46 (2.2) 1/26 (3.8) 0/18 (0) 2/90 (2.2)
t(14;18)-/BCL2+ 10/46 (21.7) 9/26 (34.6) 15/18 (83.3) 34/90 (37.8)
Total 46/46 (100) 26/26(100) 18/18 (100) 90/90 (100)
Table 7 The correlation of FL immunophenotyping and t
(14;18) translocation
Phenotype Positive t(14;18) translocation P R
n/N %
CD10 - 2/19 10.5 < 0.001 0.453
+ 50/75 66.7
BCL6 - 8/16 50.0 0.605
+ 44/77 57.1
BCL2 - 2/7 28.6 0.121
+ 49/83 59.0
MUMI - 46/64 71.9 < 0.001 −0.482
+ 5/26 19.2
*Spearman’s rank correlation. **R, Spearman’s rank correlation coefficient/rho.
n/N, number positive/total number tested. -, Negative. +, Positive.
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position of the IgH and bcl-2 genes, and causes
overexpression of BCL2, which prevents cells in follicu-
lar center from undergoing apoptosis [27]. However, this
study demonstrated no correlation between t(14;18)
translocation and BCL2 expression. Absence of BCL2
protein in t(14;18)+/BCL2- cases is partly due to muta-
tions in the BCL2 gene that eliminate the epitopes rec-
ognized by the most commonly used antibody [28]. For t
(14;18)-/BCL2+ cases, other molecular mechanisms, for
example other types of chromosomal alterations involv-
ing the BCL2 gene on chromosome 18, activation of NF-
κB signaling pathway, viral infections, cytokine effects
and interactions with cell cycle regulators [6,29]. In this
study, the consistent rate of t(14;18) translocation and
BCL2 expression decreased with the increase of grading.
83.3% of FL3B were t(14;18) translocation-/BCL2+,
suggesting a potential different pathogenesis compared
with FL3A (34.6%) and FL1-2 (21.7%).
The value of grading FL has been debated since the
1980s. The 2008 WHO grades classification maintains a
histological grading system (grades 1–3) for FL. It has
been suggested that the number of grades could beTable 5 Correlation between CD10 and MUM1 protein
expression in the FL
CD10 P* R**
- +
MUM1 - 9 69 0.005 −0.269
+ 11 21
*Spearman’s rank correlation. **R, Spearman’s rank correlation coefficient/rho.
FL, follicular lymphomas.reduced, since FL1 and FL2 are clinically indolent and
pathologically similar. Our study revealed that low-grade
FL had a high homogeneity in morphology, immune
phenotype and t(14;18) translocation. FL3A and FL3B
showed significant heterogeneity in t(14;18) translocation
and MUM1 expression, although both types showed cer-
tain homogeneity in morphology and immunophenotype
(CD10, BCL2 and BCL6). Consistent with previous studied
[16,30], FL3A was genetically similar to low-grade FL, while
FL3B was more similar to DLBCL in t(14;18) translocation.
In conclusion, our study revealed that FL1 and FL2 were
immunophenotypically and genomically similar, while
FL3A and FL3B were partly immunophenotypically similar
but morphologically, genomically distinct. FL3A was
genomically closer to FL1-2, whereas FL3A was genomically
closer DLBCL. CD10- FL was correlated with MUM1+ and
t(14;18)-,suggesting its potentially different origin or patho-
genesis from other subgroups. Thus we hypothesize that
FL may in fact be a heterogeneous indolent lymphoma
encompassing entities with distinct molecular pathogenesis
and genetic characteristics. Immunohistochemical and gen-
etic characterization helps to distinguish subgroups of FLs.
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